Apparent treatment-resistant hypertension and cardiorenal outcomes

Apparent treatment-resistant hypertension (aTRH) is associated with adverse cardiovascular and kidney outcomes, but contemporary real-world estimates that account for time at risk and distinguish incident from pre-existing disease remain limited. We performed a retrospective cohort study of 83,156 adults receiving outpatient care at Naples Comprehensive Health between April 2022 and April 2024. Baseline blood pressure (BP) phenotype was determined from the first recorded office BP and the antihypertensive medication list, with goals individualised by cardiovascular disease (CVD) history (< 130/80 mm Hg with CVD; <140/90 mm Hg without CVD). Patients were classified as having normal BP, controlled BP on therapy, uncontrolled hypertension not meeting resistance criteria (non-TRH), or aTRH. The primary outcome was a composite of incident myocardial infarction, stroke, or heart failure. For every outcome, patients with that condition recorded at baseline were excluded from the denominator. Associations were estimated with multivariable Poisson models incorporating a person-time offset, yielding incidence rate ratios (IRRs); all-cause mortality was analysed with Cox proportional hazards regression. Among 83,156 adults, 7,299 (8.8%) met criteria for aTRH, of whom 5,362 (73.5%) were above goal on three or more agents and 1,937 (26.5%) were at goal on four or more. Over 130,618 person-years (mean follow-up 18.8 months), the incidence of the primary composite outcome rose stepwise across phenotypes, from 25.6 per 1,000 person-years with normal BP to 132.7 with aTRH. After adjustment for age, sex, race, diabetes, prior CVD, smoking, obesity, chronic kidney disease, dyslipidaemia and malignancy, aTRH was associated with the primary composite outcome (IRR 2.46; 95% CI, 2.26–2.68), heart failure (3.31; 2.96–3.69), acute kidney injury (2.86; 2.53–3.24), chronic kidney disease (2.45; 2.23–2.69), end-stage kidney disease (4.46; 2.50–7.96) and all-cause mortality (hazard ratio 1.78; 1.41–2.26). aTRH was persistent: 68.4% remained in the aTRH category at follow-up, whereas 22.7% transitioned to controlled BP. Findings were unchanged across four alternative phenotype definitions. In routine outpatient care, aTRH affected approximately one in eleven adults, was largely persistent over a mean of 18.8 months, and was independently associated with incident cardiovascular and kidney disease and with death. The gradient was steepest for heart failure and kidney outcomes, supporting earlier recognition and systematic treatment optimisation.

Authors

Institutions

Publication Details

Journal
BMC Cardiovascular Disorders
Published
2026-11-18
DOI
https://doi.org/10.1186/s12872-026-06853-y
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Apparent treatment-resistant hypertension and cardiorenal outcomes

Mazen Saadi Albaghdadi, Michael N. Young, Emily V. Kassar, Felix Mahfoud et al.
BMC Cardiovascular Disorders
Blood Pressure and Hypertension Studies
article

Apparent treatment-resistant hypertension and cardiorenal outcomes

Mazen Saadi Albaghdadi, Michael N. Young, Emily V. Kassar, Felix Mahfoud, Robert J. Cubeddu, Eric Alexander Secemsky, Nicole Mamprejew, Andreas Sarantopoulos, Steven Miller, Mohammed Alvi, David Linz, Ammar Abu Sulb, Luis Paz
article en

Abstract

Apparent treatment-resistant hypertension (aTRH) is associated with adverse cardiovascular and kidney outcomes, but contemporary real-world estimates that account for time at risk and distinguish incident from pre-existing disease remain limited. We performed a retrospective cohort study of 83,156 adults receiving outpatient care at Naples Comprehensive Health between April 2022 and April 2024. Baseline blood pressure (BP) phenotype was determined from the first recorded office BP and the antihypertensive medication list, with goals individualised by cardiovascular disease (CVD) history (< 130/80 mm Hg with CVD; <140/90 mm Hg without CVD). Patients were classified as having normal BP, controlled BP on therapy, uncontrolled hypertension not meeting resistance criteria (non-TRH), or aTRH. The primary outcome was a composite of incident myocardial infarction, stroke, or heart failure. For every outcome, patients with that condition recorded at baseline were excluded from the denominator. Associations were estimated with multivariable Poisson models incorporating a person-time offset, yielding incidence rate ratios (IRRs); all-cause mortality was analysed with Cox proportional hazards regression. Among 83,156 adults, 7,299 (8.8%) met criteria for aTRH, of whom 5,362 (73.5%) were above goal on three or more agents and 1,937 (26.5%) were at goal on four or more. Over 130,618 person-years (mean follow-up 18.8 months), the incidence of the primary composite outcome rose stepwise across phenotypes, from 25.6 per 1,000 person-years with normal BP to 132.7 with aTRH. After adjustment for age, sex, race, diabetes, prior CVD, smoking, obesity, chronic kidney disease, dyslipidaemia and malignancy, aTRH was associated with the primary composite outcome (IRR 2.46; 95% CI, 2.26–2.68), heart failure (3.31; 2.96–3.69), acute kidney injury (2.86; 2.53–3.24), chronic kidney disease (2.45; 2.23–2.69), end-stage kidney disease (4.46; 2.50–7.96) and all-cause mortality (hazard ratio 1.78; 1.41–2.26). aTRH was persistent: 68.4% remained in the aTRH category at follow-up, whereas 22.7% transitioned to controlled BP. Findings were unchanged across four alternative phenotype definitions. In routine outpatient care, aTRH affected approximately one in eleven adults, was largely persistent over a mean of 18.8 months, and was independently associated with incident cardiovascular and kidney disease and with death. The gradient was steepest for heart failure and kidney outcomes, supporting earlier recognition and systematic treatment optimisation.

BMC Cardiovascular Disorders
Dartmouth–Hitchcock Medical Center (US), Beth Israel Deaconess Medical Center (US), Harvard University (US), University of Toronto (CA), Naples Community Hospital Healthcare System (US), University Hospital of Basel (CH), Deaconess Hospital (US)
Good health and well-being
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon